The Relationship between Intracellular Protein Kinase C Concentration and Invasiveness in U-87 Malignant Glioma Cells.
- Author:
Cheol JI
1
;
Kyung Keun CHO
;
Kyung Jin LEE
;
Sung Chan PARK
;
Jung Ki CHO
;
Joon Ki KANG
;
Chang Rak CHOI
Author Information
1. Catholic Neuroscience Center, Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
U-87 malignant glioma cell;
Protein kinase C;
Invasion
- MeSH:
Animals;
Biology;
Brain;
Brain Neoplasms;
Cell Line;
Drug Therapy;
Glioblastoma;
Glioma*;
Humans;
Phosphotransferases;
Prognosis;
Protein Kinase C*;
Protein Kinases*;
Rats;
Signal Transduction;
Tamoxifen
- From:Journal of Korean Neurosurgical Society
2001;30(3):263-271
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Glioblastomas, the most common type of primary brain tumors, are highly invasive and cause massive tissue destruction at both the tumor invading edges and in areas that are not in direct contact with glioma cells. As a result, patients with high-grade gliomas are faced with a poor prognosis. Such grim statistics emphasize the need to better understand the mechanisms that underlie glioma invasion, as these may lead to the identification of novel targets in the therapy of high grade gliomas. Protein kinase C(PKC) is a family of serine/threonine kinases and an important signal transduction enzyme that conveys signals generated by ligand-receptor interaction at the cell surface to the nucleus. PKC appears to be critical in regulating many aspects of glioma biology. The purpose of this study was to assess accurately the role of PKC in the invasion regulation of human gliomas based on hypothesis that protein kinase C(PKC) is functional in the process of glial tumor cell invasion. METHOD: To test this hypothesis, U-87 malignant glioma cell line intracellular PKC levels were up and down regulated and their invasiveness was tested. Intracellular PKC level was characterized using PKC activity assays. Invasion assays including barrier migration and spheroid confrontation were used to study the relationship between PKC concentration and invasiveness. RESULT: The cell line which were treated by PKC inhibitor tamoxifen and hypericin exhibited decreased PKC activity and decreased invasive abilities dose dependently both in matrigel invasion assay and tumor spheroid fetal rat brain aggregates(FRBA) confrontation assay. However, the cell line that was treated by PKC activator 12-O-tetradecanylphorbol-13acetate(TPA) did not exhibit increases in either PKC activity or invasive ability. CONCLUSION: These studies suggest that PKC may be a useful molecular target for the chemotherapy of glioblastoma and other malignancies and that a therapeutic approach based on the ability of PKC inhibitors may be helpful in preventing invasion.
